Disease-free survival did not differ significantly between patients who received leucovorin and fluorouracil versus those who received capecitabine in adjusted analyses ( hazard ratio -LSB- HR -RSB- @ -LSB- @-@ ; p = @ -RSB- ) or in unadjusted analyses ( HR @ -LSB- @ % CI @-@ ; p = @ -RSB- ) .